Allelica Advances the Front Line of Early Breast Cancer Detection with Cambridge

Early detection saves lives. In breast cancer, the difference between population-level screening and individualized risk assessment can determine not only when cancer is detected—but whether it can be prevented or mitigated at all.

In January, Allelica announced a meaningful step forward in that evolution: a commercial license agreement with Cambridge Enterprise to incorporate the BOADICEA v7 breast cancer risk prediction model into Allelica’s clinical risk assessment platform. For women—and for clinicians responsible for their care—this represents a convergence of the most rigorously validated breast cancer risk science with a modern, clinically deployable precision-medicine infrastructure.

Why This Matters

Breast cancer risk assessment has historically relied on blunt instruments: age-based screening guidelines, limited family history, and population averages that fail to capture individual genetic reality. While monogenic testing (e.g., BRCA1/2) has been transformative for a subset of patients, it explains only a fraction of who will actually develop breast cancer. The missing link has been integration.

The BOADICEA model—developed at the University of Cambridge and validated over decades—helps Allelica do that.

By licensing BOADICEA v7 for commercial clinical use, Allelica is now authorized to bring this gold-standard framework directly into routine care—where decisions about screening cadence, prevention strategies, and patient management actually happen.

Allelica’s Differentiated Approach

Valor led Allelica’s seed round in 2021 with a clear conviction: polygenic risk scores would become a foundational layer of modern medicine, not a niche research tool. What distinguished Allelica then—and continues to today—was not just scientific ambition, but execution discipline. The team recognized early that clinical adoption requires far more than statistical accuracy. It requires:

Regulatory-grade validation
Seamless clinical workflows
Interpretability for healthcare professionals
And critically, multi-ancestry performance to avoid the bias that has plagued much of genomics to date

Since that initial investment, Allelica has executed at pace—building partnerships with Illumina, Thermo Fisher, Labcorp, and Invitae; serving leading research hospitals including Mayo Clinic, Stanford, Scripps, and Cleveland Clinic; and achieving acceptance by major insurers. The integration of BOADICEA builds directly on this foundation. By combining BOADICEA’s validated monogenic and clinical framework with Allelica’s multi-ancestry polygenic infrastructure, clinicians receive a more complete, clinically aligned view of breast cancer risk—one that reflects how risk is truly evaluated in real-world settings.

As Allelica CEO and Co-Founder Giordano Botta, PhD, noted:

“Accurate breast cancer risk assessment requires the integration of monogenic and polygenic genetic variation alongside established clinical risk factors. This license allows us to combine validated monogenic and polygenic risk, and clinical factors into a unified framework that reflects how risk is evaluated in real clinical settings.

For women, this means earlier identification of elevated risk, more personalized screening strategies, and the opportunity for prevention rather than reaction. For healthcare systems, it means moving beyond one-size-fits-all medicine toward precision at population scale.

A Signal for the Future of Women’s Health

This announcement is not just about breast cancer. It is a signal of where medicine is heading: toward integrated, AI-enabled risk intelligence that is equitable, actionable, and clinically trusted.

Allelica’s work demonstrates what it looks like when frontier science meets operational rigor—and when technology is built not just to predict risk, but to change outcomes.